drugset / Trial / NCT00306878
Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical research study is to determine the safety, pharmacokinetics, immunogenicity in humans, the recovery time required from the biologic effects and the optimal biologic dose range of BMS188667 (CTLA4Ig)
Timeline
- Start
- 1995-08
- Primary completion
- 1997-05
- Completion
- 1997-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abatacept | Other / unclassified | — | — |